

Product Information



Fatty Acid Amide Hydrolase Blocking Peptide

Item No. 301600

Fatty acid amide hydrolase (FAAH) catalyzes the hydrolysis of biologically significant fatty acid amides.¹ Characterization of FAAH, its substrates, and inhibitors have helped to partially elucidate molecular regulation of sleep,² nociception,^{3,4} and cancer.⁵ FAAH is an intracellular enzyme linked to the plasma-membrane *via* its N-terminal domain.^{6,7} The purified enzyme from rat has an estimated molecular mass of 63,000.⁶ Cloning and characterization of porcine, murine, and human FAAH indicate a high degree of homology with the rat sequence.^{7,8} Northern and immunoblot analyses reveals that FAAH exists in a wide variety of tissues and is particularly abundant in liver, pancreas, brain, testes, uterus, small intestine, and ocular tissue.^{1,7,9,10}

Laboratory Procedures

This vial contains 200 µg blocking peptide in 200 µl TBS, pH 7.4, containing 0.02% sodium azide. It was derived from the C-terminus of the rat FAAH sequence (amino acids 561-579; CLRFMREVEQLMTPQKQPS)¹¹ can be used in conjunction with Cayman's FAAH Polyclonal Antibody (Item No. 101600) to block protein-antibody complex formation during immunochemical analysis of XXX.

Store this peptide solution at -20°C. It will be stable for at least two years. To block antibody/protein complex formation, the following procedure is recommended:

1. Mix the FAAH Polyclonal Antibody (Item No. 101600) and blocking peptide together in a XX:XX (v/v) ratio in a microfuge tube. For example, mix 20 µl of antibody and 20 µl of peptide.*
2. Incubate for 1 hour at room temperature with occasional mixing prior to further dilution and application of the mixture to the immunoblot.
3. Dilute the mixture to the final working antibody concentration and apply to the slide or membrane as usual.

*This is a recommended mixture. The minimum amount of peptide needed for complete blocking has not been precisely determined and may vary depending on the sample being analyzed. The amount of peptide required may need to be increased if sufficient blocking does not occur.

References

1. Fowler, C.J., Jonsson, K.-O., and Tiger, G. *Biochem. Pharmacol.* **62**, 517-526 (2001).
2. Boger, D.L., Henriksen, S.J., and Cravatt, B.F. *Current Pharmaceutical Design* **4**, 303-314 (1998).
3. Cravatt, B.F., Demarest, K., Patricelli, M.P., *et al. Proc. Natl. Acad. Sci. USA* **98(16)**, 9371-9376 (2001).
4. Di Marzo, V., Bisogno, T., Melck, D., *et al. FEBS Lett.* **436**, 449-454 (1998).
5. Bisogno, T., Katayama, K., Melck, D., *et al. Eur. J. Biochem.* **254**, 634-642 (1998).
6. Cravatt, B.F., Giang, D.K., Mayfield, S.P., *et al. Nature* **384**, 83-87 (1996).
7. Giang, D.K. and Cravatt, B.F. *Proc. Natl. Acad. Sci. USA* **94**, 2238-2242 (1997).
8. Goparaju, S.K., Kurahashi, Y., Suzuki, H., *et al. Biochim. Biophys. Acta* **1441**, 77-84 (1999).
9. Katayama, K., Ueda, N., Kurahashi, Y., *et al. Biochim. Biophys. Acta* **1347**, 212-218 (1997).
10. Van Sickle, M.D., Oland, L.D., Ho, W., *et al. Gastroenterology* **121**, 767-774 (2001).
11. Tsou, K., Nogueron, M.I., Muthian, S., *et al. Neurosci. Lett.* **254**, 137-140 (1998).

Related Product

Fatty Acid Amide Hydrolase Polyclonal Antibody - Item No. 101600

WARNING: THIS PRODUCT IS NOT INTENDED OR APPROVED FOR HUMAN OR VETERINARY USE. USE OF THIS PRODUCT FOR HUMAN OR ANIMAL TESTING IS EXTREMELY HAZARDOUS AND MAY RESULT IN DISEASE, SEVERE INJURY, OR DEATH.

MATERIAL SAFETY DATA

This material should be considered hazardous until information to the contrary becomes available. Do not ingest, swallow, or inhale. Do not get in eyes, on skin, or on clothing. Wash thoroughly after handling. This information contains some, but not all, of the information required for the safe and proper use of this material. Before use, the user must review the complete Material Safety Data Sheet, which has been sent *via* email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Cayman Chemical Company makes **no warranty or guarantee** of any kind, whether written or oral, expressed or implied, including without limitation, any warranty of fitness for a particular purpose, suitability and merchantability, which extends beyond the description of the chemicals hereof. Cayman **warrants only** to the original customer that the material will meet our specifications at the time of delivery.

Cayman will carry out its delivery obligations with due care and skill. Thus, in no event will Cayman have **any obligation or liability**, whether in tort (including negligence) or in contract, for any direct, indirect, incidental or consequential damages, even if Cayman is informed about their possible existence.

This limitation of liability does not apply in the case of intentional acts or negligence of Cayman, its directors or its employees.

Buyer's **exclusive remedy** and Cayman's sole liability hereunder shall be limited to a refund of the purchase price, or at Cayman's option, the replacement, at no cost to Buyer, of all material that does not meet our specifications.

Said refund or replacement is conditioned on Buyer giving written notice to Cayman within thirty (30) days after arrival of the material at its destination. Failure of Buyer to give said notice within thirty (30) days shall constitute a waiver by Buyer of all claims hereunder with respect to said material.

For further details, please refer to our Warranty and Limitation of Remedy located on our website and in our catalog.

Copyright Cayman Chemical Company, 02/17/2011

Cayman Chemical

Mailing address

1180 E. Ellsworth Road
Ann Arbor, MI
48108 USA

Phone

(800) 364-9897
(734) 971-3335

Fax

(734) 971-3640

E-Mail

custserv@caymanchem.com

Web

www.caymanchem.com